Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 15.35% |
| Q3 2025 | 12.82% |
| Q2 2025 | -4.77% |
| Q1 2025 | -17.18% |
| Q4 2024 | 40.74% |
| Q3 2024 | 6.24% |
| Q2 2024 | 3.45% |
| Q1 2024 | -7.39% |
| Q4 2023 | -4.14% |
| Q3 2023 | -2.65% |
| Q2 2023 | 8.68% |
| Q1 2023 | 7.59% |
| Q4 2022 | 16.52% |
| Q3 2022 | 1.94% |
| Q2 2022 | 16.86% |
| Q1 2022 | -1.19% |
| Q4 2021 | 19.95% |
| Q3 2021 | 3.27% |
| Q2 2021 | 57.85% |
| Q1 2021 | -5.98% |
| Q4 2020 | 80.24% |
| Q3 2020 | 12.71% |
| Q2 2020 | 27.26% |
| Q1 2020 | 0.00% |